Aurobindo Pharma shares in focus after fire at Andhra Pradesh facility; operations paused for 20-25 days

[hfe_template id='11223'] [ad_1]
Aurobindo Pharma shares will be in focus on Tuesday after the company reported a fire incident at its Penicillin-G manufacturing facility in Kakinada SEZ, Andhra Pradesh, on April 27, 2025.

The fire, which occurred around 10 PM IST, affected the coal crusher area, damaging some ancillary equipment. However, the core manufacturing infrastructure remained unaffected, and no injuries were reported.


"On April 27, 2025, at approximately 10:00 PM (IST), a fire incident occurred in the vicinity of the coal crusher area at our Penicillin-G manufacturing facility located in Kakinada SEZ, Thondangi (M), Kakinada District - 533449, Andhra Pradesh, India," Aurobindo Pharma said in a regulatory filing.

The company clarified that the incident is not expected to have a material impact on operations or financials. A thorough damage assessment is underway, and as a precautionary measure, plant operations will be paused for an estimated 20–25 days to replace damaged equipment.


The fire, caused by the self-ignition of coal, is under investigation. Aurobindo Pharma assured that the facility is fully insured and that it remains committed to resuming operations as soon as possible, in compliance with safety and quality standards.

This facility belongs to Aurobindo’s wholly-owned step-down subsidiary, Lyfius Pharma Private Limited.

Aurobindo Pharma Share Price Target


According to Trendlyne data, the average target price for Aurobindo Pharma is Rs 1,471, suggesting an 18% upside from current levels. Among 28 analysts, the consensus rating is 'Buy'.From a technical standpoint, the stock’s Relative Strength Index (RSI) stands at 62.1, indicating it is neither oversold nor overbought (RSI below 30 is considered oversold, and above 70, overbought).

The Moving Average Convergence Divergence (MACD) is at 12.3, above its center and signal line, signaling a bullish trend.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, and 100-day simple moving averages (SMAs), but below its 150-day and 200-day SMAs.

Also Read: Jio Financial Services, Polycab among 10 largecap stocks where FIIs cut stakes in Q4 FY25

Aurobindo Pharma Share Price Performance


On Monday, Aurobindo Pharma shares closed 2.4% higher at Rs 1,246.7 on the BSE. The stock has gained 10% over the last three months and 102% over the past two years. Its current market capitalization stands at Rs 72,411 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)

[ad_2] Source link https://mrgaga.in/aurobindo-pharma-shares-in-focus-after-fire-at-andhra-pradesh-facility-operations-paused-for-20-25-days/?feed_id=48442&_unique_id=68107379b5383

Comments

Post a Comment

Popular posts from this blog

India VIX jumps 100% in one month. Could fear levels take Nifty further down?

Image
[hfe_template id='11223'] [ad_1] Volatility in Indian equity markets has surged sharply over the past month, with the India VIX nearly doubling as geopolitical tensions and global uncertainty triggered aggressive selling in equities. India VIX, often referred to as the market’s fear gauge, has jumped close to 100% over the past month, reflecting growing nervousness among investors. The spike has coincided with a sharp correction in the broader market, with the Nifty 50 declining about 8% during the same period. The escalation of tensions involving the United States, Israel and Iran has intensified market anxiety in recent days, pushing crude oil prices sharply higher and triggering a global risk-off sentiment. However, analysts note that volatility had already been building even before the conflict escalated, reflecting broader concerns around global growth, foreign capital outflows and stretched valuations in equities. The heightened uncertainty translated into a sharp ...
Read more

Can Sensex, Nifty snap 2-day fall on Monday? 7 factors that could decide market mood this week

Image
[hfe_template id='11223'] [ad_1] Benchmark indices Sensex and Nifty ended the week on a bearish note, closing over a percent lower each as a deepening selloff in IT stocks rattled investor sentiment amid mounting fears of AI-led disruption. Further, stronger-than-expected jobs data for January dampened hopes of a US Fed interest rate cut. Here are 7 factors that could decide market action in the coming week: 1.) Infosys, Wipro ADRs rebound - After a brutal two-day selloff that saw Infosys and Wipro ADRs plunge as much as 14.5%, Friday’s session brought a much-needed breather. Bargain hunting kicked in at lower levels, sparking a sharp rebound as Infosys climbed 3% while Wipro gained 4%—helping both stocks close the week on a far stronger note. International brokerage firm JP Morgan has a message for panic-stricken investors: IT services firms are the indispensable "plumbers of the tech world" and their dividend yields have now hit levels last seen only during ...
Read more

Waaree Energies shares in focus after Q4 profit rises 34% to Rs 619 crore, revenue up 36%

Image
[hfe_template id='11223'] [ad_1] Waaree Energies shares will be in focus on Wednesday after the solar panel maker reported a strong Q4 performance, with net profit rising 34.1% year-on-year (YoY) to Rs 618.9 crore for the quarter ended March 31, 2025. In the same quarter last year, the company had reported a profit of Rs 461.5 crore. Revenue from operations jumped 36.4% to Rs 4,003.9 crore, up from Rs 2,935.8 crore in the year-ago period, according to the company’s regulatory filing. EBITDA more than doubled to Rs 922.6 crore in Q4 FY25, up 120.6% from Rs 418.3 crore in the same quarter last year. The EBITDA margin improved to 23% from 14.3% a year ago. The company produced 2.06 GW of solar modules in the fourth quarter, up from 1.35 GW in the same period last year. For the full year, module production reached 7.13 GW, compared to 4.77 GW in FY24. For the full financial year FY25, revenue rose 27.62% YoY to Rs 14,846.06 crore. Profit after tax more than doubled to Rs 1,9...
Read more